Product Description
Mechanisms of Action: PTX2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Amyloidosis
Phase 1: Amyloidosis|Cardiomyopathies
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03417830 |
NCT03417830 | P1 |
Terminated |
Cardiomyopathies|Amyloidosis |
2018-07-20 |
4% |
2019-03-22 |
Treatments |
NCT01777243 |
NCT01777243 | P1 |
Completed |
Amyloidosis |
2015-12-22 |
2019-03-19 |
Treatments |
|
NCT03044353 |
NCT03044353 | P2 |
Terminated |
Amyloidosis |
2019-01-03 |
73% |
2019-04-03 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
2016-000276-23 |
2016-000276-23 | P2 |
Completed |
Amyloidosis |
2019-01-03 |
73% |
2022-03-13 |
Treatments |